Patents by Inventor Nicholas Baumhover

Nicholas Baumhover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers
    Patent number: 12337042
    Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.
    Type: Grant
    Filed: July 12, 2024
    Date of Patent: June 24, 2025
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Dongyoul Lee, Michael K. Schultz, Mengshi Li, Nicholas Baumhover, F. Christopher Pigge
  • FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES
    Publication number: 20250186631
    Abstract: The present invention relates to a fibroblast activation protein alpha (FAP)-targeting peptides A-[Z-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Z]—B. A is N-terminal structure. B is C-terminal structure, and each of the Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7 is a residue of an amino acid. The peptides can be linear or cyclized.
    Type: Application
    Filed: July 9, 2024
    Publication date: June 12, 2025
    Applicant: Viewpoint Molecular Targeting, Inc.
    Inventors: Michael K. Schultz, Mengshi Li, Brianna S. Cagle, Nicholas Baumhover, Ivy Vance, Dijie Liu, Samuel Rodman, III
  • FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES
    Publication number: 20250186630
    Abstract: The present invention relates to a fibroblast activation protein alpha (FAP)-targeting conjugate comprising Formula I: Y-L-X, wherein Y is a chelator or cytotoxic drug, L is a linker, and X is a molecule comprising a cyclic peptide of formula A-[Z-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Z]-B A is N-terminal structure. B is C-terminal structure, and each of the Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7 is a residue of an amino acid.
    Type: Application
    Filed: December 12, 2023
    Publication date: June 12, 2025
    Applicant: Viewpoint Molecular Targeting, Inc.
    Inventors: Michael K. Schultz, Mengshi Li, Brianna S. Cagle, Nicholas Baumhover, Ivy Vance, Dijie Liu, Samuel Rodman, III
  • Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for Cancers
    Publication number: 20240366816
    Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.
    Type: Application
    Filed: July 12, 2024
    Publication date: November 7, 2024
    Applicant: University of Iowa Research Foundation
    Inventors: Dongyoul Lee, Michael K. Schultz, Mengshi Li, Nicholas Baumhover, F. Christopher Pigge
  • STRUCTURAL OPTIMIZATION METHOD TO IMPROVE THE THERANOSTIC PERFORMANCE OF PEPTIDE RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR CANCERS
    Publication number: 20230105344
    Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.
    Type: Application
    Filed: January 28, 2021
    Publication date: April 6, 2023
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Dongyoul Lee, Michael K. Schultz, Mengshi Li, Nicholas Baumhover, F. Christoper Pigge